Omalizumab May Elevate Risk of Cardio...

General Practice     Red Alerts September 26, 2014   ROCKVILLE, Md -- September 26, 2014 -- A review of safety studies by the US Food and Drug Administration (FDA) suggests a slightly increased risk of cardiovascular and cerebrovascular adverse events among patients being treated with the asthma drug omalizumab (Xolair) than in those who were not... Read more   DG Alerts helps you protect your patients and prepare your practice by staying informed of disease outbreaks, drug recalls, and other public health threats. SEND FEEDBACK © 2014 Doctor's Guide Publishing Limited. All rights reserved. 1140 Avenue of the Americas, 14th Floor New York, NY 10036 Change Your Password Edit Profile |  Terms of Use |  Privacy Policy |  Unsubscribe